(Q48066731)

English

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

scientific article published on 9 December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. (English)

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

anti-retroviral agent

0 references

Vicente Soriano

6

object named as

Vincent Soriano

1 reference

Europe PubMed Central

8 February 2018

author name string

Carolina Garrido

1

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Anna Maria Geretti

2

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Natalia Zahonero

3

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Clare Booth

4

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Angela Strang

5

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Carmen De Mendoza

7

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

language of work or name

0 references

publication date

9 December 2009

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

65

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

2

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

320-326

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Integrase polymorphism and HIV-1 group O diversity

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Raltegravir treatment response in an HIV-2 infected patient: a case report

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Raltegravir and etravirine are active against HIV type 1 group O.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKP423

21 January 2018

Identifiers

10.1093/JAC/DKP423

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/20007331

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48066731&oldid=1267466334"